BlueRock’s Photoreceptor Cell Therapy to Move into Clinical Trial
Автор: Restore Optic Nerve Function
Загружено: 2024-12-04
Просмотров: 369
Описание:
BlueRock Therapeutics, a cell therapy company and wholly owned subsidiary of Bayer AG, has received authorization from the US Food & Drug Administration to launch a Phase 1/2 clinical trial for OpCT-001, a photoreceptor cell therapy for people with inherited retinal diseases such as retinitis pigmentosa and cone-rod dystrophy.
--------------------------------------------------------------------------------------
For more information on emerging therapies and online order of the products for restore vision, please visit our website: http://www.restorevisionherbs.com
For more information and online order of AC STIM:
https://www.restorevisionherbs.com/pr...
For more information about H2 vision, please check:
https://www.restorevisionherbs.com/h2...
For information about V20 Light, please check:
https://www.restorevisionherbs.com/v2...
For more information and online order of StemActiv :
https://www.restorevisionherbs.com/st...
For more information about OCU-ION:
https://www.restorevisionherbs.com/oc...
Contact us for any question about restore vision:
[email protected]
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
